Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 7, Pages e41865
Publisher
Public Library of Science (PLoS)
Online
2012-07-28
DOI
10.1371/journal.pone.0041865
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY
- (2012) Clapton Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 antibody reduces LDL cholesterol
- (2012) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
- (2011) Jacques Genest et al. CANADIAN JOURNAL OF CARDIOLOGY
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- Statin-induced myopathy: a review and update
- (2011) Thura T Abd et al. Expert Opinion On Drug Safety
- Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
- (2011) Fen Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of genes involved in cholesterol uptake and transport in H295R adrenocortical cells
- (2011) Natasha C. Lucki et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The annexin A2 system and vascular homeostasis
- (2011) Elle C. Flood et al. VASCULAR PHARMACOLOGY
- Beyond LDL Cholesterol, a New Role for PCSK9
- (2010) Omar N. Akram et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22
- (2010) A Cenarro et al. CLINICAL GENETICS
- A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1
- (2010) Alice Marques-Pinheiro et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effects of the Prosegment and pH on the Activity of PCSK9
- (2010) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
- (2010) Yan G. Ni et al. JOURNAL OF LIPID RESEARCH
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
- (2010) Richard Kones Drug Design Development and Therapy
- Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort
- (2009) John F. Thompson et al. Circulation-Cardiovascular Genetics
- The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis
- (2009) Philippa J. Delahoy et al. CLINICAL THERAPEUTICS
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
- (2009) Noam Zelcer et al. SCIENCE
- Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
- (2008) Robert J. Schmidt et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
- (2008) LiXin Shan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PCSK9 as a therapeutic target of dyslipidemia
- (2008) Nabil G Seidah EXPERT OPINION ON THERAPEUTIC TARGETS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- The activation and physiological functions of the proprotein convertases
- (2008) N SEIDAH et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
- (2008) Yi Luo et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started